SQI Diagnostics Inc.

Equities

SQD.H

CA78466B1085

Advanced Medical Equipment & Technology

Delayed Toronto S.E. Other stock markets 11:00:00 2023-07-12 EDT			5-day change	1st Jan Change
- ^CAD	-.--%		-100.00%	-100.00%

2023	SQI Diagnostics Announces Resignation of Wilmot L. Matthews as Director	CI
2023	Clive J. Beddoe Announces Resignation as Director of SQI Diagnostics Inc	CI

SQI Diagnostics Inc. Reports Earnings Results for the Year Ended September 30, 2013

January 28, 2014 at 04:30 pm

SQI Diagnostics Inc. reported earnings results for the year ended September 30, 2013. For the year, net loss was $6,207,000 ($0.15 net loss per share) as compared to $6,311,000 $0.17 net loss per share for the year ended September 30, 2012.

Latest news about SQI Diagnostics Inc.

SQI Diagnostics Announces Resignation of Wilmot L. Matthews as Director	11-30	CI
Clive J. Beddoe Announces Resignation as Director of SQI Diagnostics Inc	11-30	CI
SQI Diagnostics Announces Receipt of Intention to Enforce Security from Pivot Financial and Anticipated Voluntary Bankruptcy Filing	23-06-16	CI
SQI Diagnostics Inc. Announces Executive Changes	23-06-06	CI
SQI Diagnostics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-29	CI
SQI Diagnostics Inc. Extends Maturity Date of Pivot Credit Facility and Deferral of Certain Interest Payments	23-05-08	CI
SQI Diagnostics Inc. to Focus on Development of Point of Care Products in Respiratory Health	23-03-28	CI
SQI Diagnostics Inc. Enters into New Consulting Agreement with Looking Glass Capital Consultants	23-03-13	CI
SQI Diagnostics Inc. Announces Four Diagnostic Products in the Pipeline	23-03-03	CI
SQI Diagnostics Down Near 40% After Citing Liquidity, Going Concern; Reports Fiscal Q1 Loss	23-03-02	MT
SQI Diagnostics Brief: Down Near 40% After Citing Liquidity and Going Concern As Reported First Quarter 2023 Results	23-03-02	MT
SQI Diagnostics Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	23-03-01	CI
SQI Diagnostics Extends Maturity of $7.5 Million Credit Facility	23-02-06	MT
SQI Diagnostics Inc. Extends Maturity Date of Pivot Credit Facility and Deferral of Certain Interest Payments	23-02-06	CI
SQI Diagnostics Inc. Auditor Raises 'Going Concern' Doubt	23-01-29	CI
SQI Diagnostics Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	23-01-29	CI
SQI Installs Two Rali-Dx Systems in Toronto Hospitals to Fight the Growing Respiratory Health Crisis in Emergency Departments	23-01-18	CI
SQI Diagnostics Inc. announced that it has received CAD 1.15 million in funding	22-12-15	CI
SQI Diagnostics Completes First Tranche of Private Placement, Details Acquisition of Securities By Wilmot Matthews	22-12-05	MT
SQI Diagnostics Plans to Raise $1 Million via Private Placement	22-11-25	MT
SQI Diagnostics Reports Sale of Shares by Board Chairman	22-11-24	MT
SQI Diagnostics Inc. announced that it expects to receive CAD 1 million in funding	22-11-23	CI
SQI Diagnostics Inc. announced that it expects to receive CAD 2 million in funding from Federal Economic Development Agency for Southern Ontario	22-11-09	CI
SQI Diagnostics Extending Maturity Date of Pivot Credit Facility and Announcing Deferral of Certain Interest Payments	22-10-19	MT
SQI Diagnostics Inc. Extends Maturity Date of Pivot Credit Facility	22-10-19	CI

Chart SQI Diagnostics Inc.

Duration

Period

More charts

Company Profile

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Companyâs TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-12-10 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
SQI DIAGNOSTICS INC.	-100.00%	4.46M
THERMO FISHER SCIENTIFIC	+6.45%	213B
DANAHER CORPORATION	+9.84%	184B
INTUITIVE SURGICAL, INC.	+28.86%	153B
BOSTON SCIENTIFIC CORPORATION	+34.22%	113B
SIEMENS HEALTHINEERS AG	+0.80%	63.66B
EDWARDS LIFESCIENCES CORPORATION	+18.69%	53.53B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+0.13%	49.11B
AGILENT TECHNOLOGIES, INC.	-4.11%	38.73B
GE HEALTHCARE TECHNOLOGIES INC.	+2.28%	36.26B

Other Advanced Medical Equipment & Technology